[{"id":"1b7129d0-6d4a-47c4-a842-fca0760d89ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588440","created_at":"2022-10-20T14:11:47.879Z","updated_at":"2024-07-02T16:35:27.535Z","phase":"Phase 1/2","brief_title":"A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies","source_id_and_acronym":"NCT05588440","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ONCT-808"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2037","study_completion_date":" 12/01/2037","last_update_posted":"2023-11-30"}]